Qiming U.s. Ventures Management 13F annual report
Qiming U.s. Ventures Management is an investment fund managing more than $52.6 billion ran by Ryan Baker. There are currently 6 companies in Mr. Baker’s portfolio. The largest investments include Jasper Therapeutics Inc and Korro Bio Inc, together worth $33.6 billion.
$52.6 billion Assets Under Management (AUM)
As of 6th August 2024, Qiming U.s. Ventures Management’s top holding is 928,964 shares of Jasper Therapeutics Inc currently worth over $21.1 billion and making up 40.1% of the portfolio value.
Relative to the number of outstanding shares of Jasper Therapeutics Inc, Qiming U.s. Ventures Management owns less than approximately 0.1% of the company.
In addition, the fund holds 368,085 shares of Korro Bio Inc worth $12.5 billion.
The third-largest holding is Tourmaline Bio Inc worth $9.54 billion and the next is Hillevax Inc worth $8.08 billion, with 558,923 shares owned.
Currently, Qiming U.s. Ventures Management's portfolio is worth at least $52.6 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Qiming U.s. Ventures Management
The Qiming U.s. Ventures Management office and employees reside in Bellevue, Washington. According to the last 13-F report filed with the SEC, Ryan Baker serves as the Chief Financial Officer at Qiming U.s. Ventures Management.
One of the smallest hedge funds
The two most similar investment funds to Qiming U.s. Ventures Management are Kitching Partners and Autonomy Capital (jersey) L.P.. They manage $52.7 billion and $52.6 billion respectively.
Ryan Baker investment strategy
Qiming U.s. Ventures Management’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Finance — making up 40.1% of
the total portfolio value.
The fund focuses on investments in the United States as
33.3% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
17% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $232 million.
The complete list of Qiming U.s. Ventures Management trades based on 13F SEC filings
These positions were updated on August 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Jasper Therapeutics Inc |
No change
928,964
|
$21,087,483,000 | 40.07% |
| Korro Bio Inc |
No change
368,085
|
$12,467,039,000 | 23.69% |
| Tourmaline Bio Inc |
No change
741,691
|
$9,538,146,000 | 18.13% |
| Hillevax Inc |
No change
558,923
|
$8,082,027,000 | 15.36% |
| Ventyx Biosciences Inc |
No change
412,225
|
$952,240,000 | 1.81% |
| Kezar Life Sciences Inc |
No change
828,711
|
$497,227,000 | 0.94% |
| No transactions found | |||
| Showing first 500 out of 6 holdings | |||
Hedge funds similar to Qiming U.s. Ventures Management
- Roumell Asset Management
- Hawkeye Capital Management
- Spinecap Sas
- Advanced Portfolio Management
- Union Square Park Capital Management
- Antara Capital L.P.
- Kitching Partners
- Autonomy Capital (jersey) L.P.
- Intrepid Family Office
- Atlas Advisors
- Mudrick Capital Management, L.P.
- Innovius Capital Management
- 1060 Capital
- Trellus Management